Exelixis announces breakthrough therapy designation granted to cabozantinib for the treatment of patients with previously treated radioactive iodine-refractory differentiated thyroid cancer

Exelixis

25 February 2021 - Exelixis expects to submit supplementary New Drug Application in 2021.

Exelixis today announced that the U.S. FDA has granted breakthrough therapy designation to cabozantinib (Cabometyx) as a potential treatment for patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Read Exelixis press release

Michael Wonder

Posted by:

Michael Wonder